Aging immune cells run out of energy and turn on joints in rheumatoid arthritis
A new review argues that metabolic exhaustion in aging immune cells, including NAD+ and ATP depletion, drives inflammatory cell death and explains why RA hits older adults.
Resumen
Rheumatoid arthritis (RA) most often affects people over 50. This review by Weyand and Goronzy proposes that aging immune cells lose metabolic resilience: they sense nutrients poorly, switch fuels less flexibly, and struggle to balance building and breaking down molecules. In RA, damaged mitochondria worsen this, leaving cells short of NAD+ and ATP. The oxygen-poor, nutrient-scarce joint lining adds more stress. Instead of dying quietly, these cells die through inflammatory routes such as pyroptosis and PANoptosis. In T cells, mitochondrial injury leads to gasdermin D pores and cell rupture. In synovial MerTK+ reparative macrophages, C1q signaling activates SARM1, which breaks down NAD+ and triggers cell death. The authors suggest metabolic exhaustion and organelle breakdown turn immune cells into tissue-damaging effectors, helping explain RA susceptibility with age. This is a narrative review, so it frames a hypothesis rather than proving it.
Resumen detallado
Rheumatoid arthritis is far more common in adults over 50, which suggests that immune aging, not just autoimmunity, shapes who gets the disease. Understanding this link could point to treatments that restore cellular resilience rather than only suppressing inflammation.
This Nature Reviews Rheumatology article synthesizes mechanistic research on how aging and RA affect immune cell metabolism. Only the abstract was available for this summary, so details of the evidence base are not covered here. The authors discuss innate and adaptive immune cells, including T cells and synovial macrophages.
The central argument is that older immune cells lose metabolic flexibility, nutrient sensing, and anabolic-catabolic balance. In RA, mitochondrial insufficiency adds to this, producing NAD+ and ATP scarcity and diverting carbon away from oxidative phosphorylation. The hypoxic, nutrient-poor synovium then overwhelms cells with limited adaptive capacity. In RA T cells, mitochondrial injury triggers maladaptive stress responses, disrupts communication among mitochondria, lysosomes, and the endoplasmic reticulum, and leads to gasdermin D pore formation and inflammatory lysis. In MerTK+ reparative macrophages, autocrine C1q sensing activates mitochondrial SARM1, degrading NAD+, depleting ATP, and causing PANoptosis.
The authors frame metabolic exhaustion and organelle disintegration as unifying mechanisms that convert immune cells into tissue-damaging effectors. This supports exploring NAD+ biology, mitochondrial health, SARM1, and cell-death pathways as therapeutic targets in RA.
Caveats: this is a review, not a clinical trial. Most mechanistic findings likely come from cell and tissue studies, and no evidence is presented here that boosting NAD+ or targeting these pathways helps patients. The authors also disclose industry consulting ties, including one author's stock options in a longevity company.
Hallazgos clave
- RA disproportionately affects adults over 50, linking age-related immune remodelling to loss of tolerance and autoreactivity.
- Aged and RA immune cells show mitochondrial insufficiency with NAD+ and ATP scarcity and reduced oxidative phosphorylation.
- Bioenergetic fragility pushes cells toward inflammatory, non-apoptotic death, including pyroptosis and PANoptosis.
- In RA T cells, mitochondrial injury drives gasdermin D pore formation and inflammatory cell lysis.
- In synovial MerTK+ macrophages, C1q-driven SARM1 activation depletes NAD+ and ATP, causing PANoptotic death.
Metodología
This is a narrative review that synthesizes mechanistic studies on immune aging and metabolism in rheumatoid arthritis. Based on the abstract alone, the literature search method and study selection criteria are not described.
Limitaciones del estudio
As a review summarized from its abstract only, the strength of the underlying evidence cannot be assessed, and much of it is likely preclinical or from patient-derived samples. Causality in humans and therapeutic benefit remain unproven. The authors report industry consulting relationships, including stock options in a longevity company.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: